Alcon, the global leader in eye care and a division of Novartis, announced today that it has entered into a strategic alliance with PowerVision, Inc., a privately-held, US-based medical device company focused on developing fluid-based lens implants.

PowerVision, Inc. has developed an accommodating IOL (AIOL) which has demonstrated in pilot studies the ability to change focus via a fluid-driven shape-changing technology. The AIOL is intended for cataract patients who also have presbyopia. The technology utilizes the eye’s natural accommodating muscles to transport fluid in the intraocular lens which is implanted in the eye’s capsular bag.

“We are committed to finding and developing the best, most innovative treatment option for cataract patients who live with presbyopia,” said Michael Onuscheck, Global Surgical Franchise Head, Alcon. “The fluid-based technology that PowerVision, Inc. is working on represents a potential game-changer in the category with the promise to offer patients a natural, continuous range of near to far vision.”

“We are excited about our new alliance with Alcon, and look forward to working together to bring this exciting technology to market,” said Barry Cheskin, President and CEO and Co-Founder of PowerVision.

Currently, most intraocular lenses which are used to treat presbyopia, an eye condition that occurs as part of natural aging, are multifocal IOLs which work by distributing light between different focal points allowing patients to see at multiple distances. Accommodating IOLs utilize the natural contraction of the eye’s muscle to actively focus on close objects, providing patients with a continuous range of vision.

Alcon’s investment in PowerVision, Inc., will fund further development and clinical trials, and provide Alcon the option to acquire the company.